Attend the FierceBiotech Executive Breakfast at JPM
Join us on January 14th at the Fairmont San Francisco. Register today.
Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.
Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.
The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.